Pfizer's Paxlovid not included in China's national insurance
53 Articles
53 Articles
Pfizer’s Paxlovid not included in China’s national insurance
TAIPEI >> Chinese health care authorities declined to include Pfizer’s COVID-19 treatment drug in a national reimbursement list that would have allowed patients to get it at a cheaper price throughout the country, saying it was too expensive.
Pfizer's Paxlovid not included in China's national insurance
China's health care authorities declined to include Pfizer's COVID-19 treatment drug in a national reimbursement list that would have allowed patients to get it at a cheaper price throughout the country, saying it was too expensive.
Pfizer's Paxlovid Not Included in China's National Insurance
TAIPEI, Taiwan — China’s health care authorities declined to include Pfizer’s COVID-19 treatment drug in a national reimbursement list that… Continue reading Pfizer’s Paxlovid Not Included in China’s National Insurance The post Pfizer’s Paxlovid Not Included in China’s National Insurance appeared first on The National Herald.
Pfizer's Paxlovid not included in China's national insurance
TAIPEI, Taiwan: China's health care authorities declined to include Pfizer's COVID-19 treatment drug in a national reimbursement list that would have allowed patients to get it at a cheaper price throughout the country, saying it was too expensive. Paxlovid, an oral medicine developed by New York-based dru
Pfizer's Paxlovid not included in China's national insurance
TAIPEI, Taiwan (AP) — China's health care authorities declined to include Pfizer's COVID-19 treatment drug in a national reimbursement list that would have allowed patients to get it at a cheaper price throughout the country, saying it was too expens
Coverage Details
Bias Distribution
- 55% of the sources lean Left
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage